Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT05119179

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Led by The University of Texas Health Science Center, Houston · Updated on 2026-03-17

300

Participants Needed

1

Research Sites

257 weeks

Total Duration

On this page

Sponsors

T

The University of Texas Health Science Center, Houston

Lead Sponsor

V

Vanderbilt University Medical Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obesity, cardiovascular disease, renal disease, and other related diseases.

CONDITIONS

Official Title

Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men and women aged 18 years and older
  • Diagnosis of prediabetes defined by impaired fasting glucose (100-125 mg/dL), impaired glucose tolerance (140-199 mg/dL after 75-gram oral glucose), or hemoglobin A1C between 5.7% and 6.4%
  • High risk for diabetes progression with obesity (BMI 60; 30 kg/m2) and/or metabolically unhealthy status defined by at least two of the following: elevated blood pressure (SBP 60; 130 mmHg and/or DBP 60; 85 mmHg), elevated triglycerides 60; 150 mg/dL, low HDL cholesterol (males <40 mg/dL; females <50 mg/dL), or elevated fasting glucose 60; 100 mg/dL
  • Women of childbearing potential must agree to use effective pregnancy prevention methods during the study
  • Laboratory values: hematocrit 60; 34 vol%, estimated glomerular filtration rate 60; 60 mL/min/1.73 m2, AST (SGOT) and ALT (SGPT) < 2.5 times upper limit of normal, alkaline phosphatase < 2.5 times upper limit of normal
Not Eligible

You will not qualify if you...

  • History of type 1 or type 2 diabetes mellitus
  • Pregnant or breastfeeding women
  • Use of metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, thiazolidinediones, insulin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, or corticosteroids in the past 3 months
  • Active cancer
  • Significant cardiac, liver, pancreatic, or kidney disease
  • History of serious allergic reaction to study medication or other incretin mimetics
  • Prisoners or involuntarily incarcerated individuals
  • History of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2)
  • Family history of medullary thyroid cancer, MEN 2, or any thyroid cancer
  • Hospitalization for COVID-19 in the last 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UTHealth Clinical Research Unit (CRU) at UT Brownsville

Brownsville, Texas, United States, 78520

Actively Recruiting

Loading map...

Research Team

N

Norma Perez-Olazaran

CONTACT

R

Rocio Uribe

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here